Global Porcine Vaccine Market Size By Disease Indication (Swine Influenza, Diarrhea, Arthritis), By Technology (Inactivated vaccines, Live attenuated vaccines, Recombinant vaccines), By Geographic Scope And Forecast
Published on: 2024-08-06 | No of Pages : 320 | Industry : latest updates trending Report
Publisher : MIR | Format : PDF&Excel
Global Porcine Vaccine Market Size By Disease Indication (Swine Influenza, Diarrhea, Arthritis), By Technology (Inactivated vaccines, Live attenuated vaccines, Recombinant vaccines), By Geographic Scope And Forecast
Porcine Vaccine Market Size And Forecast
Porcine Vaccine Market size was valued at USD 2.19 Billion in 2024 and is projected to reach USD 3.83 Billion by 2031, growing at a CAGR of 7.27% from 2024 to 2031.
Some of the key contributing factors propelling the growth of the Global Porcine Vaccine Market are an increase in pork consumption and a rise in the prevalence of swine diseases. Also, governments across the globe are spending higher in the field of animal health care. The Global Porcine Vaccine Market report provides a holistic evaluation of the market for the forecast period. The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market.
Global Porcine Vaccine Market Definition
Vaccines are the most important disease prevention tools for both animals and humans. Vaccination is regarded as a boon in veterinary pharmaceuticals for preserving animal welfare by avoiding the spread of many endemic diseases. Porcine vaccines are used clinically to improve swine health and protect them from deadly diseases by guarding them against viruses, bacteria, and other pathogens.
Such diseases include porcine reproductive and respiratory virus (PRRSV), swine influenza, and porcine circovirus-associated disease (PCVAD) among others. It also increases the yield of high-quality meat for human consumption while improving overall efficiency in protecting pigs from deadly viruses. In North America and Europe, many diseases like cholera, foot & mouth disease have been significantly eliminated by using these vaccines.
What's inside a
industry report?
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Global Porcine Vaccine Market Overview
The increase in pork consumption is an important driver for the Global Porcine Vaccine Market. This increase in consumption is expected to result in a greater need to keep the swine population free of any disease that could affect them and pose a threat to humans. Thus the demand for swine vaccines that guards against various porcine diseases is expected to rise.
Also, higher instances of swine flu, porcine epidemic diarrhea (PED), and porcine reproductive and respiratory syndrome (PRRS) in farms worldwide have led to an increase in early vaccination of piglets. Other important drivers are the increasing number of awareness programs about porcine diseases and increased government funding for animal health care.
Technological advancements and growing research and development are expected to provide new profitable opportunities leading to the growth of the Global Porcine Vaccine Market. Combined vaccine production gives a good opportunity for growth. Also, DNA vaccines allow agriculture farmers to produce disease-free swine on their farms. Thus, there are ample growth opportunities for the market. However, there are some restraints like the high cost of maintaining, transportation, and storage of vaccines that are expected to adversely impact the growth of the Porcine Vaccine industry.
Global Porcine Vaccine Market Segmentation Analysis
The Global Porcine Vaccine Market is segmented on the basis of Disease Indication, Technology, And Geography.
Porcine Vaccine Market, By Disease Indication
- Swine Influenza
- Diarrhea
- Arthritis
- Porcine Reproductive and Respiratory Syndrome
- Porcine Circovirus Associated Disease
- Others
Based on Disease Indication, The market is segmented into Swine Influenza, Diarrhea, Arthritis, Porcine Reproductive and Respiratory Syndrome, Porcine Circovirus Associated Disease, and Others. Diarrhea and swine influenza dominate the Global Porcine Vaccine Market owing to factors like changes in climate including global warming and overfeeding of protein diet among others.
Porcine Vaccine Market, By Technology
- Inactivated vaccines
- Live attenuated vaccines
- Recombinant vaccines
- DNA vaccines
- Others
Based on Technology, The market is segmented into Inactivated vaccines, Live attenuated vaccines, Recombinant vaccines, DNA vaccines, and Others. Inactivated vaccines are leading the market. DNA vaccines are gaining popularity in veterinary hospitals as they have several advantages over live attenuated vaccines and inactivated vaccines.
Porcine Vaccine Market, By Geography
- North America
- Europe
- Asia Pacific
- Rest of the world
On the basis of Geography, The Global Porcine Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America leads the Global Porcine Vaccine Market by geography due to the rise in pork consumption, increasing instances of various swine diseases, and higher per-capita animal healthcare expenditure in the United States. The Asia Pacific region will have good growth due to increasing awareness about porcine health, and growing advancements in the field of biotechnology.
Key Players
The “Global Porcine Vaccine Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bayer AG, Hipra, Ceva Sante Animale, Eli Lilly and Company, Merck & Co. Inc., Sanofi S.A, Zoetis Inc., Arko Laboratories Ltd, and Vetoquinol. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Key Developments
- On August 5, 2021 Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-based biopharmaceutical company that specializes in novel detection technology to unlock high-volume, uncontrolled traditional therapies with specific therapies. The Vividion platform is capable of producing a wide range of therapeutic approaches to small molecules in all directions, with an initial focus on oncology and immunology. Vividion’s leading programs include a wide range of oncology specification and immunology guidelines, with ongoing efforts to counteract NRF2 antagonism for the possible treatment of NRF2 cancer, and NRF2 activists for various inflammatory diseases such as acute intestinal disease – among other treatment programs.
- On February 18, 2021 Philippe Mauguin, INRAE chief executive officer and Drs. Marc Prikazsky, Chairman and CEO of Ceva Santé Animale (Ceva), signed a first-round agreement aimed at consolidating their animal health partnerships. This signature comes in the context of Covid-19 disease and the outbreak of bird flu in France. It affirms the shared goal of working together for the “One Health”, global health concept at animal crossroads, human and environmental health and, in particular, to prevent infectious diseases from the environment and to improve animal welfare.
Report Scope
REPORT ATTRIBUTES | DETAILS |
---|---|
STUDY PERIOD | 2021-2031 |
BASE YEAR | 2024 |
FORECAST PERIOD | 2024-2031 |
HISTORICAL PERIOD | 2021-2023 |
UNIT | Value (USD Billion) |
KEY COMPANIES PROFILED | Bayer AG, Hipra, Ceva Sante Animale, Eli Lilly and Company, Merck & Co. Inc., Sanofi S.A, Zoetis Inc., Arko Laboratories Ltd, and Vetoquinol |
SEGMENTS COVERED |
|
CUSTOMIZATION SCOPE | Free report customization (equivalent to up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope |
Research Methodology of Market Research
To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .
Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support
Customization of the Report
• In case of any please connect with our sales team, who will ensure that your requirements are met.